Matthew E. Korenberg - Sep 16, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Matthew E. Korenberg
Stock symbol
LGND
Transactions as of
Sep 16, 2024
Transactions value $
$226
Form type
4
Date filed
9/18/2024, 07:55 PM
Previous filing
Aug 26, 2024
Next filing
Sep 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $51K +914 +1.85% $55.75 50.4K Sep 16, 2024 Direct
transaction LGND Common Stock Tax liability -$50.9K -485 -0.96% $105.00 49.9K Sep 16, 2024 Direct
transaction LGND Common Stock Options Exercise $49.7K +849 +1.7% $58.49 50.8K Sep 16, 2024 Direct
transaction LGND Common Stock Tax liability -$49.6K -472 -0.93% $105.00 50.3K Sep 16, 2024 Direct
transaction LGND Common Stock Options Exercise $33.5K +671 +1.33% $49.99 51K Sep 16, 2024 Direct
transaction LGND Common Stock Tax liability -$33.5K -319 -0.63% $105.00 50.7K Sep 16, 2024 Direct
transaction LGND Common Stock Options Exercise $204K +3.34K +6.59% $60.94 54K Sep 16, 2024 Direct
transaction LGND Common Stock Tax liability -$203K -1.94K -3.59% $105.00 52.1K Sep 16, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -671 -11.09% $0.00 5.38K Sep 16, 2024 Common Stock 671 $49.99 Direct F1
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -914 -3.4% $0.00 25.9K Sep 16, 2024 Common Stock 914 $55.75 Direct F2
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -849 -6.38% $0.00 12.5K Sep 16, 2024 Common Stock 849 $58.49 Direct F3
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -3.34K -15.29% $0.00 18.5K Sep 16, 2024 Common Stock 3.34K $60.94 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F2 This Option was previously reported as a Grant of 30,750 shares on February 13, 2020, at an exercise price of $95.68 per share , but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on February 13, 2024.
F3 This Option was previously reported as a Grant of 15,225 shares on February 24, 2017, which vested in full on February 24, 2021, at an exercise price of $100.38 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F4 This Option was previously reported as a Grant of 25,000 shares on August 06, 2015, which vested in full on August 06, 2019, at an exercise price of $104.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.